Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U1 small nuclear 76, pseudogene (RNU1-76P) is a member of the U1 small nuclear RNA pseudogene family. Pseudogenes are genomic DNA sequences similar to normal genes but are typically non-functional due to mutations or lack of regulatory elements, and do not encode functional products[5][4][6]. RNU1-76P is specifically annotated as a pseudogene for U1 small nuclear RNA, which, in its functional (non-pseudogene) forms, plays an essential role in spliceosome assembly and the splicing of pre-mRNA. However, RNU1-76P itself is not known to be transcribed into a functional RNA, and there is no evidence it acts as a receptor, enzyme, transporter, or therapeutic target. Therefore, it is not considered a drug target or relevant for biomarker development or disease association[5][4][6]. The gene is present in genome annotations (e.g., as HGNC:48418, Ensembl: ENSG00000199773, NCBI Gene: 106481617), but is mostly listed for reference and not for active biological or clinical roles[5].\n\nKey points:\n- This gene is a **pseudogene**—it does not code for a functional molecule[5][4][6].\n- It is not considered a **therapeutic target** because pseudogenes, by definition, lack function.\n- There are no known biological functions, disease associations, or drug interactions related to RNU1-76P[5][4][6].\n- Its only common alias is RNU1-76P.\n- Its family (U1 snRNA or small nuclear RNA) is important for mRNA splicing, but this pseudogene does not participate in these activities.\n\nThere is nothing misspelled in the target’s name, but the **inquiry as a therapeutic target is incorrect**, as pseudogenes are not molecular targets for therapeutic intervention[5][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 76, pseudogene (RNU1-76P).